(Reuters) – Spanish pharmaceutical firm Almirall reported on Monday core earnings of 51.8 million euros ($57.19 million) in the first quarter, boosted by European dermatology growth, beating analysts’ estimates polled by Refinitiv.
EBITDA fell 13.1% from the same period one year ago, the company said in a statement.
(Reporting by Matteo Allievi and Jakub Olesiuk; Editing by Edmund Klamann)
